Search This Blog

Saturday, June 14, 2025

NYT and conflict of interest: Where have they been?

 

Secretary Kennedy
The and other Pharma-funded MSM outlets contacted my office this morning, feigning indignation that has a conflict that they suggest might impair his scientific judgment as a member of the new ACIP panel. The NY Times’ sudden squeamishness about conflicts of interest on the ACIP panel begs the question: Where has the Times been for the last 20 years during which individual panelists regularly voted to recommend new vaccines owned by companies with which they personally had obscene financial conflicts? The New York Times reporter objected to the fact that, in 2017, Malone drafted an expert report for a federal case on behalf of a whistleblower, Merck’s laboratory director Stephen Krahling, who accused the company of forcing him to falsify lab reports to inflate the efficacy of the mumps component of its MMR jab. The Times claims that its “experts believe” that Malone’s involvement in these legal proceedings should make him ineligible to vote on future ACIP recommendations. In fact, HHS will, for the first time in history, institute bias policies recommending that ACIP panelists recuse themselves from decisions in which their current or former clients have a financial interest. Vaccine mandates give these panelists the awesome power to guarantee billion-dollar annual profits to their Pharma benefactors from trapped markets of 74 million American children now compelled to purchase a zero-liability product with no legitimate safety testing. Despite years of complaints about conflicts and corruption at ACIP—from congress, the HHS inspector General, and others—the mainstream media has largely remained silent. The single exception to this omerta has been United Press International (UPI) reporter Mark Benjamin who summarized the committee’s pervasive putrescence in 2003. Benjamin wrote that ACIP panelists often share vaccine patents, own stock in vaccine companies, “receive payment for research or to monitor vaccine trials, and receive vaccine-maker funding for their academic departments.” A 2000 Congressional investigation offered one example of those conflicts: “Four out of eight CDC advisory committee members who voted to approve guidelines for the rotavirus vaccine in June 1998 had financial ties to pharmaceutical companies that were developing different versions of the vaccine.” Despite all the critiques, my predecessors at HHS did virtually nothing to purge the corruption at ACIP. We now have a slate of scientists, physicians, and public health experts of impeccable integrity who will vote to promote public health rather than the private profit interests of the New York Times’ advertisers.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.